Image thumbnail

New Clinical Study! SlimSEB™ Keeps GLP-1 Users on Track

New Clinical Study! SlimSEB™ Keeps GLP-1 Users on Track

GLP-1 agonists have transformed weight management, but they come with a retention problem. More than 64% of adults on GLP-1s quit within a year, driven off by nausea, vomiting and indigestion.

Formulators have spotted the opening. The GLP-1 companion category is racing to fill it, and buyers want ingredients backed by real data.

A newly published clinical study delivers exactly that. Adults on GLP-1 therapy who added SlimSEB™ to their regimen saw measurable gains across gastrointestinal comfort, quality of life and body composition, giving brands the clinical evidence needed to formulate with confidence.*

Clinical Trial Designed for Real-World Relevance

The study design was simple:

  • Single-arm, placebo-controlled, sequential pilot study
  • 30 adults
  • All participants stably taking GLP-1s for at least 2 months
  • Participants maintained usual diet and daily activity
  • Participants took placebo for 30 days, followed by 30 days of SlimSEB™
  • Assessments done at baseline and end of each phase

The rigor of this protocol matters. Brands need ingredients validated in populations that mirror actual GLP-1 users, not idealized cohorts.

GI Side Effects Take a Hit

GLP-1 discontinuation almost always traces back to the gut. Nausea, bloating, indigestion and constipation chip away at compliance until people walk away from therapy entirely.

Study results show SlimSEB™ directly addresses this pain point:

  • 27% decrease in abdominal pain*
  • 21% reduction in indigestion*
  • 26% decrease in constipation*

No adverse events or serious adverse events occurred during the study, reinforcing SlimSEB™’s safety and tolerability profile.*

Quality of Life Gains

Participants taking SlimSEB™ reported meaningful, statistically significant improvements across several domains compared to the placebo:

  • 29% reduction in bodily pain*
  • 25% improvement in social functioning*
  • 12% increase in energy & vitality*
  • 5% improvement in physical functioning*

Mental health and general health scores also improved significantly within the SlimSEB™ group.*

Anthropometric Results Outpace Placebo

SlimSEB™ outperformed the placebo, delivering statistically significant reductions across every anthropometric measure, including:

  • 5 lb greater weight loss*
  • 11 cm greater reduction in waist circumference*
  • 86% greater reduction in body fat*
  • 36 kg/m2 greater decrease in BMI*

Add it up and a picture emerges: a supplement that supports whole-body wellness, not just a single biomarker.*

Science Behind the Results

The synergistic SlimSEB™ formula combines digestive enzymes, targeted probiotics and herbal extracts to work across multiple biological pathways simultaneously:

  • A proprietary enzyme converts dietary sucrose into slowly digestible and indigestible fiber, supporting healthy glucose metabolism & feeding beneficial gut bacteria*
  • Targeted probiotic strains colonize the gut to promote a balanced microbiome & hunger hormone modulation*
  • Green tea & mulberry leaf extracts deliver antioxidant and anti-inflammatory support that promotes healthy lipid metabolism & satiety*

It’s a multi-mechanism approach that explains why SlimSEB™ moves the needle across such a broad range of outcomes, from gut comfort to quality of life to body composition.*

SlimSEB™

Your Competitive Edge in a Crowded Category

Brands developing metabolic health, weight management, or GLP-1 companion products now have another peer-reviewed, published clinical study backing SlimSEB™’s efficacy and safety.

Consumers increasingly demand transparency and evidence. Regulators scrutinize weight management claims more closely than ever. Partnering with an ingredient manufacturer that invests in rigorous clinical research hands brands the substantiation needed to make confident, defensible claims.

SlimSEB™ earns its place in the GLP-1 conversation through data, not hype. Solid science drives its effectiveness, and this latest clinical trial adds to a growing body of evidence behind a formula designed to help your customers sustain therapy, protect their gut and reclaim their quality of life.*

Ready to explore how SlimSEB™ can elevate your next companion product? Reach out to our team to review the full study data and discuss how to integrate it into your product line.

Sources

  1. Seery, C. (2025a, February 21). Diabetes.
  2. Rathi A, Chandan H, Vira C, Pore MP. Toxicology Research and Application. 2023;7. doi:10.1177/23978473231215122
  3. Rathi, A. et al. (2025). Advanced Enzymes Proprietary clinical study.
  4. Rathi, A. et al. (2026). Advanced Enzymes Proprietary clinical study.
  5. Rathi A, Pagare R, Agrawal M. Diabetes Res Open J. 2024; 10(1): 1-5.
  6. Rathi, A., Potale, S., & Rathi, V. L. (2026). International Journal of Clinical Trials, 13(1), 30–39